BEIJING (Reuters) - China’s Kintor Pharmaceutical Ltd said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that on October 1 its phase III clinical trial of proxalutamide for the treatment of hospitalized Covid-19 patients has enrolled and dosed its first patient in the United States.
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that on October 1 its phase III clinical trial of proxalutamide for the treatment of hospitalized Covid-19 patients has enrolled and dosed its first patient in the United States.
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics in China, has entered into a licensing agreement with PT Etana Biotechnologies Indonesia, on the commercialization of proxalutamide for the treatment of COVID-19 in Indonesia.
SUZHOU, China, Feb.22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients in Brazil completed the recruitment of 588 patients. The data of the clinical trial is expected to be available in March 2021.
Kintor Pharmaceutical Limited announced that the clinical trial of proxalutamide for the treatment of hospitalised Covid-19 patients in Brazil completed the recruitment of 588 patients. The data of the clinical trial is expected to be available in March 2021.